ASH 2020: Focus on Diffuse Large B-Cell Lymphoma
A study presented at the 2020 ASH Annual Meeting found that loncastuximab, a humanized anti-CD19 antibody, had ...
Guidelines from the World Health Organization and National Comprehensive Cancer Network recommend that all patients with ...
AUTO3 is a chimeric antigen receptor (CAR) T-cell targeting CD19/22 with limited duration of PD-1 blockade. A study ...
A study presented at the 2020 ASH Annual Meeting found that the efficacy of selinexor in patients with ...
Researchers assessed the use of a next-generation sequencing (NGS)-based minimal residual disease (MRD) assay for early ...
A real-world study presented at the 2020 ASH Annual Meeting observed no significant survival differences in patients ...
Acalabrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was ...
A study presented at the 2020 ASH Annual Meeting assessed whether there was a survival difference between Hispanic (HI) ...
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus lenalidomide improved response rates ...
Real-world data showed a high unmet medical need among older patients with diffuse large B-cell lymphoma (DLBCL): Up to ...
Up to one-quarter of older Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) do not receive any therapy. ...
A study presented at the 2020 ASH Annual Meeting found that R-CHOP (rituximab, cyclophosphamide, doxorubicin, ...
A study presented at the 2020 ASH Annual Meeting found that tafasitamab in combination with rituximab mediates increased ...
Odronextamab is a first-in-class, hinge-stabilized, fully human immunoglobulin G4-based CD3xCD20 bispecific antibody ...
Researchers assessed the efficacy of adding selinexor to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, ...
Barriers within oncology systems can impede patient-centered care coordination and delivery in those with ...
Advertisement
Advertisement
